- Thinly traded nano cap KemPharm (NASDAQ:KMPH) is up 35% premarket on light volume in response to its collaboration and license agreement with KVK Tech for U.S. commercial rights to APADAZ (benzhydrocodone and acetaminophen tablets).
- Under the terms of the deal, KMPH will receive up to $3.4M in pre-launch payments, up to $53M in sales milestones and half of net profits based on achieving certain sales levels.
- KVK will be responsible for all regulatory and commercialization expenses.
KemPharm out-licenses U.S. rights to Apadaz for up to $56M; shares up 35% premarket
Recommended For You
About ZVRA Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
ZVRA | - | - |
Zevra Therapeutics, Inc. |